In a large cohort of HIV-infected Tanzanians, we assessed: (i) rates of first-line treatment failure and switches to second-line ART; (ii) the effect of switching to second-line ART on death and loss to follow-up; and (iii) treatment outcomes on second-line ART by regimen.
Introduction
An estimated 35 million people worldwide are living with HIV, over two-thirds of whom reside in sub-Saharan Africa (SSA). Approximately 37% of HIV-infected individuals living in the WHO Africa region are receiving ART. 1 An increasing number of studies from this region have reported high rates of ART failure and resistance with first-line therapies, ranging from 11.1% to 24% and from 70% to 81%, respectively. [2] [3] [4] Despite relatively high rates of treatment failure, only about 3-10% of patients are switched to second-line therapy. [5] [6] [7] Delays in switch are also common, especially within HIV care and treatment programmes that rely on immunological criteria alone to detect ART failure. Studies have shown that delaying switch to second-line ART can result in accumulation of drug resistance mutations and a higher risk of virological failure (VF) with second-line regimens. 8, 9 The clinical consequences of switching ART especially after significant delays are still unclear. To date, few studies have examined the effect of switching on clinical outcomes, and all have shown a protective effect of switching on mortality. However, the degree to which switching confers a clinical benefit may be influenced by certain conditions, such as the timing after first-line ART failure at which switch occurs and criteria used to define treatment failure. [10] [11] [12] [13] [14] The objective of this study was to examine the effect of switching from first-to second-line ART on clinical outcomes in a large V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. dynamic cohort of HIV-infected Tanzanians, adjusting for confounders unaccounted for in other studies. Rates of switching as well as death and loss to follow-up among patients switched to second-line ART were also assessed.
Methods

Study design, site and population
This prospective cohort study was conducted among adult (age 15 years) patients enrolled in HIV Care and Treatment Clinics (CTCs) in Dar es Salaam (HIV prevalence 6.9% in 2013 15 ) that were supported by Management and Development for Health (MDH) under the President's Emergency Plan For AIDS Relief (PEPFAR). MDH was established in 2004 and during this study provided infrastructure, laboratory and technical support to 48 HIV CTCs in three districts of Dar es Salaam. All HIV-infected adults initiated on ART between November 2004 and September 2012, with a known first-line initiation date and who did not switch to second-line ART before 24 weeks (168 days) after first-line ART initiation were included in this study. Patients were considered eligible for second-line ART if they met VF criteria [a single HIV viral load (VL) .10000 copies/mL after 24 weeks on therapy] and/or immunological failure (IF) criteria (50% drop in CD4! T cell count from peak value and a return to pre-ART baseline CD4! T cell count or lower). The VL threshold of 10000 copies/mL was used for the determination of VF by clinicians at MDH-supported CTCs for the duration of the study according to Tanzanian (2009) and WHO (2006) guidelines.
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Ethics
Patients were recruited for participation and enrolled in MDH-supported CTCs following written informed consent, which was subject to ethical reviews by the Muhimbili University of Health and Allied Sciences and Harvard School of Public Health Institutional Review Boards.
Clinical and laboratory procedures
Clinical care of all HIV-infected patients at MDH-supported HIV CTCs follows Tanzanian and WHO guidelines. 16, 17 HIV-infected patients initiated on ART are examined monthly by a physician, undergo adherence and nutrition counselling and receive ART refills, provided free of charge by the Tanzanian government. Laboratory tests including haemoglobin, CD4! T cell count, and blood chemistries including ALT, creatinine and lipid panel are performed every 6 months. At the time of the study, HIV RNA testing was performed when antiretroviral failure was suspected based on immunological + clinical criteria and, in some patients, was conducted routinely. Patients switched to second-line ART are scheduled for visits monthly and have laboratory tests conducted similar to the schedule outlined above. Before switching to second-line ART, patients are assessed for treatment readiness, which includes a review of a risk reduction plan and the clients' understanding of ART, with their treatment assistant. At all clinics a comprehensive patient tracking system is in place to ensure that patients who have missed a visit, are lost to follow-up, are sick or have an abnormal laboratory result are contacted by phone or in person to encourage them to return to the clinic. A network of community-based health workers and volunteer persons living with HIV work with MDH to actively trace and ascertain a status on all patients who are lost to follow-up. During the study period, standard first-line ART regimens included stavudine or zidovudine, lamivudine plus efavirenz or nevirapine. In 2008, tenofovir, lamivudine or emtricitabine plus efavirenz or nevirapine became the preferred first-line regimen. Recommended second-line regimens until 2008 included the combination of abacavir ! didanosine and lopinavir/ ritonavir (or saquinavir/ritonavir). In 2009, the preferred second-line regimen became tenofovir ! lamivudine or emtricitabine ! lopinavir/ritonavir.
We defined switch to second line as a change from a first-line NNRTI-based regimen to a PI-based regimen.
Data collection and management
Patient demographic, clinical, laboratory and therapeutic data are collected by physicians and nurses on standard case report forms and National Care and Treatment Center forms (CTC 2), which are entered into a secure computerized database. Data collected for this study included gender, marital status, age, district, BMI, WHO stage, season, dates of all clinic visits, facility level, history of or current TB, co-trimoxazole use, ART regimen at initiation and follow-up, ART duration and date of loss to follow-up and/or death. Laboratory data included haemoglobin (g/dL), CD4! T cell count (/mm 3 ), ALT (IU/L) and HIV RNA copies (/mL).
Outcomes and definitions
The primary study outcomes were death, loss to follow-up and the combined outcome of death or loss to follow-up. As a secondary outcome, we assessed death and death or loss to follow-up in only patients on secondline ART. Deaths were recorded after notification by family members, friends or the patient-tracking team. If the date of death was unknown but the patient was known to have died, the date of the last encounter with the patients was used as the day of death. For patients who did not die, followup ended on 30 September 2012. Patients were considered lost to followup if the time from their last scheduled but missed appointment to the time of death or the study cut-off date was at least 90 days, or, if there was no appointment date recorded, if the time from their last visit date to the time of death or the study cut-off was at least 120 days. ART non-adherence was defined as the percentage of days in the inter-visit interval that were after the next recorded appointment date.
Statistical analysis
Proportions were used to describe categorical characteristics; means (standard deviation, SD) were used to describe continuous characteristics at the time of first-line and second-line ART initiation. Among patients who were switched to second-line ART, the comparative effectiveness of two primary second-line regimens used during the study period (abacavir and tenofovir containing) were studied. Cox models were used to calculate the HRs, comparing the relative effects of these two regimens on mortality rates, loss to follow-up rates and the combination of these two.
Three groups of patients were followed: (i) all patients who initiated first-line ART irrespective of whether they became eligible for second line or not; (ii) patients eligible for second-line ART by the IF and/or VF criteria above, whichever occurred first; and (iii) patients eligible for second-line ART by VF criteria. Survival analyses for mortality, loss to follow-up and the combined outcome were conducted with multivariate Cox proportional hazards regression. 18 For all patients on first-line ART, time began at ART initiation, while for the two second-line eligible sub-groups, time began at the date of second-line eligibility. Marginal structural models were used to adjust for potential bias due to the possibility of informative censoring and time-varying confounding by indication. 19 Modification of the effects of second-line ART use by time from second-line ART eligibility to second-line ART initiation, visit adherence, and time between first-line initiation and second-line eligibility was explored by calculating stratified estimates and testing for the significance of any differences observed through the creation of cross-product terms, multiplying the time-varying second-line use by the modifier as a continuous variable and comparing models with and without this term, with a one degree of freedom likelihood ratio test. P values less than 0.05 were considered statistically significant. All statistical analyses were performed using SAS, release 9.3 (Cary, NC, USA).
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Results
Study population and baseline characteristics (Table 1) In total, 47296 HIV-infected patients who were active in follow-up 24 weeks after initiation of first-line ART (and had not yet switched to second-line ART) were included in this analysis. The mean age at the time of initiation of first-line ART was 37.5 (SD " 9.5) years; 29% of the patients were male. Mean BMI was 21.7 (4.7) kg/m 2 . Mean CD4 T cell count was 175 (158) cells/mm 3 and over twothirds of the patients were WHO stage III or greater. Over 90% were initiated on either stavudine or zidovudine ! lamivudine and either efavirenz or nevirapine.
The overall incidence of antiretroviral failure defined by IF and/or VF criteria during follow-up was 7.1 per 100 personyears. Also, 1459/5949 of patients with VL available had VL .10000 copies/mL, and 7825/39490 (21%) with CD4 T cell count available met definition for IF. In total, 1760/47296 (3.7%) patients switched to second-line ART after at least 24 weeks of first-line ART (incidence rate overall 1.5/100 person-years); this included 368/1760 with IF, 687/1760 with VF and 705/1760 who did not meet either IF and/or VF criteria for failure or had no HIV VL or CD4 available. In total, 8229/9284 (87%) who met criteria for IF and/or VF were never switched, including 772 (8%) who were eligible by VF criteria.
Among patients who switched to second-line ART, the mean time from ART initiation to switching was 2.8 (1.4) years. For the subset of switchers who met failure criteria, the mean time from eligibility to switching was 0.9 ( Clinical outcomes among patients on second-line ART (Table 2) Of the 1760 patients who were switched to second-line ART, 1278 (73%) patients were switched to abacavir ! didanosine or lamivudine ! lopinavir/ritonavir or saquinavir/ritonavir, 410 (23%) were switched to tenofovir ! lamivudine or emtricitabine ! lopinavir/ ritonavir, and 72 (4%) were switched to another PI-based secondline regimen. The incidences of mortality, loss to follow-up or death or loss to follow-up among patients who switched to second-line ART were 2.4, 9.0 and 10.9/100 person-years, respectively ( Figure 1 ). Lower risks of loss to follow-up [7. 4/100 versus 9.3/100 person-years; adjusted HR (aHR)"0.64 (95% CI " 0.38-1.06); P " 0.08] and loss to follow-up or mortality [8.5/100 versus 11.4/100 person-years; aHR " 0.78 (95% CI " 0.49-1.25); P " 0.29] were observed in patients on tenofovir-versus abacavir-containing PI-based second-line ART after adjusting for potential confounders (footnote b Table 2 ), although none of the findings was statistically significant. The crude risk of mortality was lower in the tenofovir group (1.1/100 versus 2.5/100 person-years), but reversed after adjustment [aHR " 1.97 (95% CI " 0.58-6.66); P " 0.28]. Because these two regimens were found to be of similar effectiveness, we combined them in the analysis that follows.
Relation of switching to mortality and loss to follow-up (Table 3 and Figure 2) The overall incidence of mortality, loss to follow-up and death or loss to follow-up among all patients who had been initiated on first-line ART was 1.4, 8.3 and 9.5 per 100 person-years, respectively. In univariate analyses, the risk of all three outcomes was significantly higher in patients who switched to second-line ART than in patients who did not switch, irrespective of whether or not they were eligible to switch. Findings remained similar in multivariate analyses adjusting for baseline as well as time-dependent confounders and in marginal structural models (footnote b Table 3 ). A higher risk of mortality was also observed in switchers compared with non-switchers when restricting analyses to those who met immunological and/or virological criteria for failure and thus were eligible for switch (n " 9284). The relative risks of loss to follow-up and loss to follow-up/death in this group of switchers were also higher. When analysing only those patients who had confirmed VF (n " 1459), mortality [2.3 versus 4.1/100 person-years; aHR " 0.81 (95% CI " 0.47-1.40); P " 0.45], loss to follow-up [9.0 versus 14.3/100 person-years; aHR " 0.81 (95% CI " 0.66-0.99); P " 0.04] and mortality or loss to follow-up [10.7 versus 17.8/100 personyears; aHR " 0.78 (95% CI " 0.65-0.95); P " 0.01] were significantly lower among those who switched compared with those in this category who did not switch. In further analyses, visit adherence was found to be an important effect modifier of second-line ART on mortality and loss to follow-up. In particular, among patients eligible for second-line ART by VL criteria, switchers who were not late by more than 5% of their scheduled times had a 50% decrease in the risk of death [aHR " 0.50 (95% CI " 0.26-0.93); P " 0.03] compared with those who did not switch (P value test for interaction " 0.01). The risk of death increased as visit adherence decreased, and was not statistically significantly different from 1 at the higher levels of non-adherence. A similar but less marked pattern was seen for loss to follow-up (P value test for interaction " 0.04), with a decrease in the hazard of loss to followup in switchers in the most adherent group [aHR " 0.71 (95% CI " 0.59-1.00); P " 0.05]. Although visit adherence also modified the relationship between switching and death among those eligible by IF and/or VF (P for interaction " 0.01), the relationship was not statistically significant at any adherence level. However, a protective, but not statistically significant effect of switching was seen in patients with the best adherence. While the time from eligibility to switching, and the time from ART initiation to eligibility for second-line ART were important predictors of the outcomes, neither modified the effect of second-line ART (data not shown).
Discussion
In this large Tanzanian HIV cohort, switching to second-line ART was associated with a higher mortality rate than not switching in the majority of individuals. A protective effect of switching on mortality and other outcomes was only observed in patients with confirmed VF and high levels of adherence.
In the face of increasing reports of treatment failure in SSA, rates of switching to second-line therapies continue to remain low, 
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Switching to second-line ART and mortality JAC ranging from 3% to 10%. [20] [21] [22] A large number of patients with treatment failure defined by either immunological or virological criteria are either never switched or experience significant delays in switching. In this study, only 3.7% of patients switched to second-line therapy. Fifty-three per cent of patients with VF were never switched, despite being eligible, and the mean time to switching from the time of second-line eligibility was almost 1 year. Only 5% of patients with IF were switched, suggesting clinicians seldom use these criteria to determine switch. Similar findings have been reported elsewhere in Tanzania and SSA. 20, 23 Reasons for the low switching rates in SSA have been well documented and include concerns about non-adherence, toxicities associated with older PIs and lack of available third-line agents, which often result in second-line treatments being considered a 'last resort'. It remains to be seen whether recently implemented routine virological monitoring and the introduction of less toxic second-line regimens will improve ART switch rates in Tanzania.
Overall outcomes among patients who were switched to second-line ART are encouraging. Mortality was low (2.4/100 person-years), and mostly similar to rates observed in other studies where treatment outcomes on second line have been examined. 24, 25 Interestingly, similar rates of mortality and loss to follow-up and the combined outcome of loss to follow-up and mortality were observed regardless of the nucleoside/nucleotide In total, 47 296 patients who were followed for at least 24 weeks after ART initiation and did not initiate second-line ART before 24 weeks. c Eligibility for second-line ART based on CD4 (.24 weeks of ART and the value at ART initiation AND less than half the peak value) or VL (24 weeks after ART intitiation and HIV VL .10 000). d More than 5% of VL data missing. e Lopinavir/ritonavir in 95% and saquinavir/ritonavir or indinavir/ritonavir in 5%. f Other regimens included: d4T ! 3TC ! lopinavir/ritonavir n " 3, ZDV ! 3TC ! lopinavir/ritonavir n " 23, d4T ! ddI ! lopinavir/ritonavir n " 6, ddI ! 3TC ! lopinavir/ritonavir n " 1, d4T ! 3TC ! IDV/r n " 10, ABC ! ZDV ! lopinavir/ritonavir n " 21 and EFV ! 3TC ! lopinavir/ritonavir, n " 8. component in the second-line regimen (tenofovir versus abacavir).
In fact, in this study the majority of patients on abacavir received the combination of abacavir and didanosine, which is associated with a theoretically higher risk of resistance when used in combination. 26 The lack of observed difference between the regimens may be due to the 'monotherapy effect' of the PI, which exerts strong antiviral effects even in the presence of nucleoside resistance. In a study from the UK of HIV-infected patients who failed first-line NNRTI and two NRTIs therapy and were switched to Pl-based therapy, neither the number of new NRTIs nor the genotypic sensitivity score of the NRTI backbone had an effect on rates of treatment success with subsequent PI-based therapies. 27 Data from SSA, however, suggest maintaining nucleoside therapy in second-line regimens may still be important, as more favourable outcomes have been reported compared with patients switched to a PI alone. [28] [29] [30] Tenofovir disoproxil fumarate was also associated with a trend towards improved patient retention, presumably due to improved adherence and less toxicity.
The findings of higher mortality among switchers compared with non-switchers in all patients initiated on first-line ART and among patients with IF and/or VF contrast with other SSA studies, where a lower risk of mortality among switchers has been observed. [10] [11] [12] [13] A number of important differences could account for this discrepancy, including the size of the study populations, antiretroviral failure definitions and analytical approach. In two studies, which examined the effect of switching to second line using marginal structural models similar to ours, the timing of switch was important in the relationship between switching and mortality. In the first paper, by Petersen et al., 11 the adjusted odds of death among patients remaining on first-line therapy compared with those who had switched was 2.1 (95% CI " 1.1-4.2); when an interaction term between switching status and time was included, the protective effect of switching on mortality was only observed for the first 28 months following failure and declined over time. Of note, in their study, switching was not found to protect against mortality when patients with only VF were analysed. In the second paper, by Gsponer et al., 10 mortality was 75% lower among patients who switched to second line compared with those remaining on failing first-line therapy and a trend towards lower mortality among patients with a shorter time to first-line therapy after IF was also seen. Interestingly, although time from second-line eligibility to switching, and time from first-line ART initiation to eligibility for second-line ART were both important predictors of the mortality in our study, neither modified the effect of second-line ART. In fact, in contrast to the study by Petersen et al., 11 our data showed that the multivariable-adjusted relative risk of mortality associated with switching was higher closer to the time of eligibility to switch to second-line ART (data not shown). We hypothesize that earlier switches to second line may have been in sicker patients who were already at a higher risk of mortality after they switched.
Importantly, none of the studies mentioned above adjusted for adherence or considered it as an effect modifier. In this study, we found that adherence significantly modified the relationship of second-line ART to mortality and loss to follow-up. Among the group of patients with antiretroviral failure defined virologically, the highest level of protection from second-line switching on these outcomes was seen in patients with the highest level of adherence (.95%). At least one study has shown that nonadherence with first-line therapies is closely correlated with non-adherence to second-line therapies and to a higher chance of treatment failure. 24 We hypothesize that the lower mortality observed among the switchers with ART failure defined virologically may therefore just reflect better adherence in this group of individuals.
To our knowledge, this study is the largest to assess the effect of ART switch on mortality and other outcomes in SSA, including over 1055 patients with first-line antiretroviral failure who switched to second-line ART in the Dar es Salaam region. Compared with the studies by Gsponer et al., 10 Petersen et al.
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and Keiser et al., 12 our study had more than four times the number of deaths and three times the number of patients than each of these others. Using marginal structural models, we were able to determine the causal effect of second-line switching on mortality, reducing bias from potential confounders, which may have predetermined switch as well as bias due to dependent censoring. We were also able to examine adherence, a critical determinant of mortality and treatment success in these settings, as an effect modifier. We did not require confirmation of VF with subsequent VL measurement, although the cut-off in the definition (.10000 copies/mL) makes transient elevations in VLs or data errors unlikely in this situation. Revised Tanzanian guidelines now recommend ART switch at a lower VL cut-off: .1000 copies/mL. 31 The proportion of patients with VF who switched therapy and crude mortality among switchers versus non-switchers did not Switching to second-line ART and mortality Models using all patients on ART also control for eligibility for second-line ART by VL and CD4 criteria. For models using all patients on ART, 'baseline' means at the time of ART initiation and time is measured from that date. For models using patients eligible for second-line ART, 'baseline' means at the time of eligibility and time is measured from that date. differ materially when we conducted sensitivity analyses using this alternative VL cut-off. The criteria used to define IF are known to be imperfect measures of antiretroviral failure 32 and thus misclassification of first-line failure could have easily occurred. In addition, data on reasons for switching were not collected as part of routine medical records procedures, so we cannot rule out the possibility that switching occurred for reasons other than antiretroviral failure. However, in most instances of toxicity, switching to alternative first-line therapies is recommended by the national guidelines. In general, this misclassification tends to lead to underestimation of HR. In addition, in most of these patients, routine VL monitoring was not performed. In the total population, an estimated 0.06 VL tests were conducted per person-year. Nevertheless, we feel our data are largely representative of other HIV programmes in SSA and offer a real world perspective on patient outcomes as they relate to antiretroviral switch over the history of PEPFAR programmes up to recent times.
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In summary, our results suggest that switching patients to second line may actually be harmful in the majority of patients, especially if they are non-adherent and immunological criteria are relied upon to define failure. Our data emphasize the urgent need for more rapid expansion of VL monitoring in HIV programmes in SSA, which may improve timely switching practices and lead to better outcomes on second-line therapy. The use of point of care VL testing could further assist in rapidly identifying patients in need of antiretroviral switch. 33 Strategies to optimize adherence are crucial to the overall success of HIV therapies in these settings. Switching to second-line ART and mortality JAC
